companydata.dkcompanydata.dk

Ascendis Pharma Endocrinology Division A/S: Financial statements 2013

CVR: 32323537

Source: annual report 2013, Danish Business Authority

01/01/2013 – 31/12/2013

Ascendis Pharma Endocrinology Division A/S (CVR 32323537) has filed annual accounts for 2013. In 2013, the company reported a gross profit of DKK -46,231,581 and a net result of DKK -47,307,843. Equity in the 2013 report amounted to DKK -36,921,176.

Gross Profit
DKK -46,231,581
Profit/Loss
DKK -47,307,843
Equity
DKK -36,921,176
Total Assets
DKK 27,684,886

Official annual report

View the official annual report directly on the page with a Pro subscription.

Fetch this data via API

Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.

See the API documentation

Events in 2013

Ascendis Pharma Endocrinology Division A/S publishes interim reportJun 3, 2013

Ascendis Pharma Endocrinology Division A/S has published its interim report for the period June 29, 2012 to December 31, 2012.

ACP 30.06.2012 2 A/S changes name to ASCENDIS PHARMA, GROWTH DISORDERS DIVISION A/SJan 30, 2013

On January 30, 2013, the company changed its name from ACP 30.06.2012 2 A/S to ASCENDIS PHARMA, GROWTH DISORDERS DIVISION A/S.

About Ascendis Pharma Endocrinology Division A/S

Ascendis Pharma Endocrinology Division A/S is a Danish company of the type Aktieselskab based in Hellerup, founded in 2012. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named ASCENDIS PHARMA, GROWTH DISORDERS DIVISION A/S and ACP 30.06.2012 2 A/S. The management consists of Jan Møller Mikkelsen. The board consists of Michael Wolff Jensen (chair), Anni Lotte Kirstine Pedersen and Jan Møller Mikkelsen. The company is owned by ASCENDIS PHARMA A/S. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported revenue of EUR 140,817,000 and a net result of EUR -38,806,000 compared with EUR -121,118,000 the year before. Equity in the 2025 report amounted to EUR -935,650,000.

Source: annual report 2025, Danish Business Authority